TRIMU-5, a μ 2-opioid receptor agonist, stimulates the hypothalamo-pituitary-adrenal axis

Abstract

Previous work in our laboratory has shown that DAMGO (ICV) will cause an elevation in plasma corticosterone (CS). The effect was blocked by pretreatment with β-FNA but not by naloxonazine, suggesting indirectly that DAMGO's effect was via a μ 2-opioid receptor. TRIMU-5, a μ 2-agonist/ μ 1 antagonist, was tested in a similar series of experiments to show more directly that the effect of DAMGO to increase plasma CS was via the μ 2 receptor. Experiments were conducted on conscious, unrestrained, male Sprague-Dawley rats with chronic IV catheters and ICV cannula guides allowing for serial blood sampling and drug injection into the right lateral ventricle. During this process, animals remained isolated in sound-attenuated one-way vision boxes. TRIMU-5, 50 μg, produced a sustained increase in plasma CS for a 3-h period. The response peaked at 30 min, showing a plasma CS level of 19.7 ± 1.4 μg/dl. A lower dose, 10 μg, did not produce a significant response. A higher dose, 100 μg, produced and elevated hormone response in a pilot study but was lethal in half the animals. The plasma CS increase was blocked by pretreatment with β-FNA, 20 μg ICV, given 18 h before TRIMU-5, but was unaffected by naloxonazine pretreatment, 20 mg/kg IV, administered 18 h before TRIMU-5. These data confirm our earlier conclusion that the effect of DAMGO to elevate plasma CS was through a μ 2-opioid receptor.